Paroksetin (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Paroksetin" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

11web.archive.org

1^st place

2^nd place

4nih.gov

4^th place

8^th place

2drugs.com

399^th place

169^th place

2justice.gov

918^th place

low place

1in.gov.br

3,151^st place

low place

1tga.gov.au

3,984^th place

2,156^th place

1medicines.org.uk

3,823^rd place

3,244^th place

1medscape.com

719^th place

152^nd place

1termania.net

low place

34^th place

1fda.gov

447^th place

409^th place

1doi.org

2^nd place

5^th place

1semanticscholar.org

11^th place

51^st place

1books.google.com

3^rd place

11^th place

1handle.net

102^nd place

416^th place

1nytimes.com

7^th place

37^th place

books.google.com

Food and Drug Administration (2011). Approved Drug Products with Therapeutic Equivalence Evaluations – FDA Orange Book 31st Edition (2011): FDA Orange Book 31st Edition (2011). DrugPatentWatch.com. str. 344. ISBN 9781934899816. Arhivirano iz spletišča dne 6. marca 2019. Pridobljeno 4. marca 2019.

doi.org

Pae CU, Patkar AA (Februar 2007). »Paroxetine: current status in psychiatry«. Expert Review of Neurotherapeutics. 7 (2): 107–120. doi:10.1586/14737175.7.2.107. PMID 17286545. S2CID 34636522.

drugs.com

»Paroxetine Hydrochloride Monograph for Professionals«. Drugs.com. American Society of Health-System Pharmacists. Arhivirano iz spletišča dne 6. marca 2019. Pridobljeno 3. marca 2019.
»Paroxetine Pregnancy and Breastfeeding Warnings«. Drugs.com. Arhivirano iz spletišča dne 3. decembra 2018. Pridobljeno 3. marca 2019.

fda.gov

Fischer A (28. junij 2013). »FDA approves the first non-hormonal treatment for hot flashes associated with menopause« (tiskovna objava). Food and Drug Administration. Arhivirano iz prvotnega spletišča dne 18. januarja 2017.

handle.net

hdl.handle.net

Svetovna zdravstvena organizacija (2021). World Health Organization model list of essential medicines: 22nd list (2021). Ženeva: Svetovna zdravstvena organizacija. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

in.gov.br

Anvisa (31. marec 2023). »RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial« [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (v portugalščini). Diário Oficial da União (objavljeno 4. april 2023). Arhivirano iz spletišča dne 3. avgusta 2023. Pridobljeno 3. avgusta 2023.

justice.gov

»GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data« (tiskovna objava). United States Department of Justice, Office of Public Affairs. 2. julij 2012. Arhivirano iz spletišča dne 9. septembra 2014. Pridobljeno 6. oktobra 2015. The United States alleges that, among other things, GSK participated in preparing, publishing and distributing a misleading medical journal article that misreported that a clinical trial of Paxil demonstrated efficacy in the treatment of depression in patients under age 18, when the study failed to demonstrate efficacy.
United States ex rel. Greg Thorpe, et al. v. GlaxoSmithKline PLC, and GlaxoSmithKline LLC, , pp. 3–19 (D. Mass. 26 October 2011). Besedilo

medicines.org.uk

Sandoz Limited (21. marec 2013). »Paroxetine 20 mg Tablets – Summary of Product Characteristics (SPC)«. electronic Medicines Compendium. Datapharm Ltd. Arhivirano iz spletišča dne 3. decembra 2013. Pridobljeno 22. novembra 2013.

medscape.com

reference.medscape.com

»Paxil, Paxil CR (paroxetine) dosing, indications, interactions, adverse effects, and more«. Medscape Reference. WebMD. Arhivirano iz spletišča dne 10. novembra 2015. Pridobljeno 22. novembra 2013.

nih.gov

pubmed.ncbi.nlm.nih.gov

Hosenbocus S, Chahal R (Februar 2011). »SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents«. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 20 (1): 60–67. PMC 3024727. PMID 21286371.
Pae CU, Patkar AA (Februar 2007). »Paroxetine: current status in psychiatry«. Expert Review of Neurotherapeutics. 7 (2): 107–120. doi:10.1586/14737175.7.2.107. PMID 17286545. S2CID 34636522.

dailymed.nlm.nih.gov

Mylan Institutional Inc. (Januar 2012). »Paroxetine (paroxetine hydrochloride hemihydrate) tablet, film coated«. DailyMed. U.S. National Library of Medicine. Arhivirano iz spletišča dne 23. oktobra 2013. Pridobljeno 22. novembra 2013.

ncbi.nlm.nih.gov

Hosenbocus S, Chahal R (Februar 2011). »SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents«. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 20 (1): 60–67. PMC 3024727. PMID 21286371.

nytimes.com

Thomas K, Schmidt MS (2. julij 2012). »Glaxo Agrees to Pay $3 Billion in Fraud Settlement«. The New York Times. Arhivirano iz spletišča dne 2. marca 2017. Pridobljeno 28. februarja 2017.

semanticscholar.org

api.semanticscholar.org

Pae CU, Patkar AA (Februar 2007). »Paroxetine: current status in psychiatry«. Expert Review of Neurotherapeutics. 7 (2): 107–120. doi:10.1586/14737175.7.2.107. PMID 17286545. S2CID 34636522.

termania.net

https://www.termania.net/slovarji/slovenski-medicinski-slovar/5531817/paroksetin?query=Paroksetin&SearchIn=All , Slovenski medicinski e-slovar, vpogled: 10. 2. 2024.

tga.gov.au

ebs.tga.gov.au

Sandoz Pty Ltd (18. januar 2012). »Product Information Paroxetine Sandoz 20Mg Film-Coated Tablets« (PDF). Therapeutic Goods Administration. Arhivirano iz spletišča dne 4. septembra 2015. Pridobljeno 22. novembra 2013.

web.archive.org

Anvisa (31. marec 2023). »RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial« [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (v portugalščini). Diário Oficial da União (objavljeno 4. april 2023). Arhivirano iz spletišča dne 3. avgusta 2023. Pridobljeno 3. avgusta 2023.
Sandoz Pty Ltd (18. januar 2012). »Product Information Paroxetine Sandoz 20Mg Film-Coated Tablets« (PDF). Therapeutic Goods Administration. Arhivirano iz spletišča dne 4. septembra 2015. Pridobljeno 22. novembra 2013.
Mylan Institutional Inc. (Januar 2012). »Paroxetine (paroxetine hydrochloride hemihydrate) tablet, film coated«. DailyMed. U.S. National Library of Medicine. Arhivirano iz spletišča dne 23. oktobra 2013. Pridobljeno 22. novembra 2013.
Sandoz Limited (21. marec 2013). »Paroxetine 20 mg Tablets – Summary of Product Characteristics (SPC)«. electronic Medicines Compendium. Datapharm Ltd. Arhivirano iz spletišča dne 3. decembra 2013. Pridobljeno 22. novembra 2013.
»Paxil, Paxil CR (paroxetine) dosing, indications, interactions, adverse effects, and more«. Medscape Reference. WebMD. Arhivirano iz spletišča dne 10. novembra 2015. Pridobljeno 22. novembra 2013.
»Paroxetine Hydrochloride Monograph for Professionals«. Drugs.com. American Society of Health-System Pharmacists. Arhivirano iz spletišča dne 6. marca 2019. Pridobljeno 3. marca 2019.
Fischer A (28. junij 2013). »FDA approves the first non-hormonal treatment for hot flashes associated with menopause« (tiskovna objava). Food and Drug Administration. Arhivirano iz prvotnega spletišča dne 18. januarja 2017.
»Paroxetine Pregnancy and Breastfeeding Warnings«. Drugs.com. Arhivirano iz spletišča dne 3. decembra 2018. Pridobljeno 3. marca 2019.
Food and Drug Administration (2011). Approved Drug Products with Therapeutic Equivalence Evaluations – FDA Orange Book 31st Edition (2011): FDA Orange Book 31st Edition (2011). DrugPatentWatch.com. str. 344. ISBN 9781934899816. Arhivirano iz spletišča dne 6. marca 2019. Pridobljeno 4. marca 2019.
»GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data« (tiskovna objava). United States Department of Justice, Office of Public Affairs. 2. julij 2012. Arhivirano iz spletišča dne 9. septembra 2014. Pridobljeno 6. oktobra 2015. The United States alleges that, among other things, GSK participated in preparing, publishing and distributing a misleading medical journal article that misreported that a clinical trial of Paxil demonstrated efficacy in the treatment of depression in patients under age 18, when the study failed to demonstrate efficacy.
Thomas K, Schmidt MS (2. julij 2012). »Glaxo Agrees to Pay $3 Billion in Fraud Settlement«. The New York Times. Arhivirano iz spletišča dne 2. marca 2017. Pridobljeno 28. februarja 2017.